

CITATION REPORT

List of articles citing

Immunologic strategies for HIV-1 remission and eradication

DOI: 10.1126/science.1255512
Science, 2014, 345, 169-74.

Source: <https://exaly.com/paper-pdf/59486832/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
186	The transient HIV remission in the Mississippi baby: why is this good news?. 2014 , 17, 19859		20
185	Immunosuppression Induced by HIV Infection. 2014 , 06,		3
184	HIV Prevention and Treatment Fields Join Forces. 2014 , 1, 4-5		2
183	Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions. 2014 , 12, 1187-201		12
182	Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 1027-40	1.6	14
181	CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients. 2015 , 18, 20052		129
180	Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission?. 2015 , 10, 198-206		10
179	HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET. 2016 , 17, 33-45		9
178	HIV cure research: a formidable challenge. <i>Journal of Virus Eradication</i> , 2015 , 1, 1-3	2.8	11
177	The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 70, 122-8	3.1	5
176	Immunotherapeutic Approaches for the Control and Eradication of HIV. 2015 , 44, 719-30		4
175	HIV: Seeking ultimate victory. <i>Nature</i> , 2015 , 517, 281-2	50.4	3
174	Simian immunodeficiency virus infection and immune responses in the pig-tailed macaque testis. 2015 , 97, 599-609		12
173	Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy. 2015 , 137, 3678-85		24
172	Cell therapies for treatment of human immunodeficiency virus infection. 2015 , 25, 156-74		3
171	CCR5B2 mutation and HIV infection: basis for curative HIV therapy. <i>Current Opinion in Virology</i> , 2015 , 14, 24-9	7.5	40
170	HIV-1 and interferons: who's interfering with whom?. 2015 , 13, 403-13		193

169	Immuno-modulatory strategies for reduction of HIV reservoir cells. 2015 , 372, 146-58		7
168	HIV eradication symposium: will the brain be left behind?. 2015 , 21, 322-34		14
167	Bioinformatics and HIV latency. 2015 , 12, 97-106		12
166	Early ART in primary HIV infection may also preserve lymphopoiesis capability in circulating haematopoietic progenitor cells: a case report. 2015 , 70, 1598-600		4
165	HIV reservoirs as obstacles and opportunities for an HIV cure. 2015 , 16, 584-9		147
164	Advancing the HIV cure agenda: the next 5 years. 2015 , 28, 1-9		16
163	Dynamic models of viral replication and latency. 2015 , 10, 90-5		7
162	Enigma of HIV-1 latent infection in astrocytes: an in-vitro study using protein kinase C agonist as a latency reversing agent. 2015 , 17, 651-9		18
161	Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants. 2015 , 61, 1862-70		36
160	Post-treatment control: a functional cure for HIV. 2015 , 10, 1245-1256		
159	Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 36-44	1.6	19
158	The latest science from the IAS Towards an HIV Cure Symposium. <i>Journal of Virus Eradication</i> , 2016 , 2, 235-241	2.8	1
157	Immune checkpoints and the HIV-1 reservoir: proceed with caution. <i>Journal of Virus Eradication</i> , 2016 , 2, 183-186	2.8	11
156	HIV and AIDS. 2016 , 107-123		
155	Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. 2016 , 17,		12
154	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. <i>PLoS Pathogens</i> , 2016 , 12, e1005520	7.6	106
153	Viral Vaccines: Fighting Viruses with Vaccines. 2016 , 253-269		2
152	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016 , 22, 839-50	50.5	303

151	Challenges in HIV-persistent viral replication regardless of potent antiretroviral therapy. 2016 , 22, 585-6		
150	Human Immunodeficiency Viruses and Human T-lymphotropic Viruses. 2016 , 527-544		
149	Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency. 2016 , 24, 1528-37		19
148	A network intervention that locates and intervenes with recently HIV-infected persons: The Transmission Reduction Intervention Project (TRIP). 2016 , 6, 38100		43
147	In vitro effects of the small-molecule protein kinase C agonists on HIV latency reactivation. 2016 , 6, 39032		19
146	Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection. 2016 , 13, 24		22
145	Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach. 2016 , 5, e312		14
144	CRACC-targeting Fc-fusion protein induces activation of NK cells and DCs and improves T cell immune responses to antigenic targets. 2016 , 34, 3109-3118		5
143	Might dolutegravir be part of a functional cure for HIV?. 2016 , 62, 375-82		15
142	Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase. 2016 , 24, 5007-5016		26
141	Engineering hematopoietic stem cells toward a functional cure of human immunodeficiency virus infection. 2016 , 18, 1370-1381		9
140	Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016 , 540, 284-287	50.4	183
139	Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. 2016 , 3, ofw189		59
138	Persistent HIV-1 replication during antiretroviral therapy. 2016 , 11, 417-23		94
137	New concepts in HIV-1 vaccine development. 2016 , 41, 39-46		58
136	Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. 2016 , 3, ofw100		12
135	3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H. 2016 , 59, 6136-48		31
134	Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination. <i>Expert Review of Vaccines</i> , 2016 , 15, 719-29	5.2	27

133	Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA. 2016 , 54, 902-11		63
132	Early Combination Antiretroviral Therapy Limits HIV-1 Persistence in Children. 2016 , 67, 201-13		17
131	Dendritic Cells Enhance HIV Infection of Memory CD4(+) T Cells in Human Lymphoid Tissues. <i>AIDS Research and Human Retroviruses</i> , 2016 , 32, 203-10	1.6	7
130	Broadly Neutralizing Antibodies for HIV Eradication. 2016 , 13, 31-7		62
129	Markov process models of the dynamics of HIV reservoirs. 2016 , 275, 18-24		6
128	Opportunities and Challenges in Nanotechnology-enabled Antiretroviral Delivery. 2016 , 205-239		
127	In situ formation of peptidic nanofibers can fundamentally optimize the quality of immune responses against HIV vaccine. 2016 , 1, 135-143		20
126	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. 2017 , 9,		106
125	HIV Latency: Should We Shock or Lock?. 2017 , 38, 217-228		109
124	New challenges in therapeutic vaccines against HIV infection. <i>Expert Review of Vaccines</i> , 2017 , 16, 587-602		22
123	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017 , 215, 911-919	7	51
122	Exosomes in HIV infection: A review and critical look. 2017 , 53, 146-154		43
121	Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection. 2017 , 2, 163-171		37
120	Effects of exosome on the activation of CD4+ T cells in rhesus macaques: a potential application for HIV latency reactivation. 2017 , 7, 15611		26
119	Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins. <i>Journal of Virology</i> , 2017 , 91,	6.6	16
118	Strategies to limit immune-activation in HIV patients. 2017 , 15, 43-54		20
117	Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160. <i>Journal of Virology</i> , 2017 , 91,	6.6	12
116	B7-H1 Influences the Accumulation of Virus-Specific Tissue Resident Memory T Cells in the Central Nervous System. <i>Frontiers in Immunology</i> , 2017 , 8, 1532	8.4	14

115	Advancements in Developing Strategies for Sterilizing and Functional HIV Cures. 2017 , 2017, 6096134		23
114	Microbial translocation is correlated with HIV evolution in HIV-HCV co-infected patients. <i>PLoS ONE</i> , 2017 , 12, e0183372	3.7	6
113	Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. <i>PLoS Pathogens</i> , 2017 , 13, e1006285	7.6	99
112	Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. <i>PLoS Pathogens</i> , 2017 , 13, e1006740	7.4	51
111	A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study. <i>BMC Infectious Diseases</i> , 2017 , 17, 771	4	16
110	Rational design of a trisppecific antibody targeting the HIV-1 Env with elevated anti-viral activity. 2018 , 9, 877		43
109	Inefficient HIV-1 Infection of CD4 T Cells by Macrophages from HIV-1 Nonprogressors Is Associated with Altered Membrane Cholesterol and DC-SIGN. <i>Journal of Virology</i> , 2018 , 92,	6.6	13
108	The role of latency reversal agents in the cure of HIV: A review of current data. 2018 , 196, 135-139		25
107	Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?. <i>Journal of Infectious Diseases</i> , 2018 , 217, 1024-1032	7.1	14
106	Novel advances on tissue immune dynamics in HIV/simian immunodeficiency virus: lessons from imaging studies. 2018 , 13, 112-118		2
105	Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency. <i>Journal of Virology</i> , 2018 , 92,	6.6	7
104	Detection of HIV-1-specific gastrointestinal tissue resident CD8 T-cells in chronic infection. 2018 , 11, 909-920		26
103	Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3. <i>MBio</i> , 2018 , 9,	7.8	20
102	Hepatitis B Vaccination in Patients Receiving Oral Antiviral Therapy Without Hepatitis B Immunoglobulin After Liver Transplant. 2018 , 50, 3681-3688		2
101	HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates. <i>PLoS ONE</i> , 2018 , 13, e0207794	3.7	7
100	Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. <i>Nature</i> , 2018 , 563, 360-364	50.4	155
99	HIV control: Is getting there the same as staying there?. <i>PLoS Pathogens</i> , 2018 , 14, e1007222	7.6	35
98	Broadly neutralizing antibodies in HIV-1 treatment and prevention. 2018 , 6, 61-68		29

97	T Cells: Friends and Foes. <i>International Review of Cell and Molecular Biology</i> , 2018 , 341, ix-xii	6	0
96	Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV Latency Reversal. 2018 , 25, 1443-1455.e14		25
95	EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment. <i>PLoS Pathogens</i> , 2018 , 14, e1007061	7.6	24
94	Therapeutic vaccination for HIV: hopes and challenges. 2018 , 13, 408-415		19
93	Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1. <i>Frontiers in Immunology</i> , 2018 , 9, 345	8.4	38
92	Induction of Type I Interferons by Therapeutic Nanoparticle-Based Vaccination Is Indispensable to Reinforce Cytotoxic CD8 T Cell Responses During Chronic Retroviral Infection. <i>Frontiers in Immunology</i> , 2018 , 9, 614	8.4	15
91	Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection. 2018 , 19,		19
90	T-cell subset differentiation and antibody responses following antiretroviral therapy during simian immunodeficiency virus infection. 2018 , 155, 458-466		0
89	The Regulation of Inflammation by Innate and Adaptive Lymphocytes. 2018 , 2018, 1467538		71
88	Amantadine Surface-Modified Silver Nanorods Improves Immunotherapy of HIV Vaccine Against HIV-Infected Cells. 2018 , 10, 28494-28501		11
87	Factors associated with late presentation for HIV care in a single Belgian reference center: 2006-2017. 2018 , 8, 8594		19
86	Nanotechnology approaches to eradicating HIV reservoirs. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019 , 138, 48-63	5.7	21
85	The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation. <i>Acta Pharmacologica Sinica</i> , 2019 , 40, 98-110	8	13
84	The potential of engineered antibodies for HIV-1 therapy and cure. <i>Current Opinion in Virology</i> , 2019 , 38, 70-80	7.5	27
83	Risk to Nonparticipants in HIV Remission Studies With Treatment Interruption: A Symposium. <i>Journal of Infectious Diseases</i> , 2019 , 220, S1-S4	7	15
82	Nanocarriers For Vaginal Drug Delivery. <i>Recent Patents on Drug Delivery and Formulation</i> , 2019 , 13, 3-15	1.4	9
81	Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists. <i>Frontiers in Immunology</i> , 2019 , 10, 2450	8.4	33
80	T Cells: Friends and Foes. <i>International Review of Cell and Molecular Biology</i> , 2019 , 342, xi-xiv	6	1

79	The Increase of the Magnitude of Spontaneous Viral Blips in Some Participants of Phase II Clinical Trial of Therapeutic Optimized HIV DNA Vaccine Candidate. <i>Vaccines</i> , 2019 , 7,	5.3	2
78	Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV. <i>Frontiers in Immunology</i> , 2019 , 10, 2267	8.4	8
77	PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	30
76	Mechanisms of Cardiovascular Disease in the Setting of HIV Infection. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 238-248	3.8	23
75	iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. <i>Trials</i> , 2019 , 20, 361	2.8	17
74	Modeling HIV Dynamics Under Combination Therapy with Inducers and Antibodies. <i>Bulletin of Mathematical Biology</i> , 2019 , 81, 2625-2648	2.1	4
73	The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study. <i>BMC Infectious Diseases</i> , 2019 , 19, 257	4	9
72	HIV "shock and kill" therapy: In need of revision. <i>Antiviral Research</i> , 2019 , 166, 19-34	10.8	70
71	T Cell Therapy Targeted on HLA-A02 Restricted HIV Antigen Epitopes: An Open Label Cellular Therapy Trial Using CD8+ T Cell. <i>Frontiers in Immunology</i> , 2019 , 10, 437	8.4	2
70	Strategies for the cure of HIV infection. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2019 , 37, 265-273	0.1	1
69	Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4 T cell activation and HIV-1 latency reversal. <i>Science Advances</i> , 2019 , 5, eaav6322	14.3	19
68	Establishment of latent HIV-1 reservoirs: what do we really know?. <i>Journal of Virus Eradication</i> , 2019 , 5, 3-9	2.8	38
67	HIV-1 Latency and Latency Reversal: Does Subtype Matter?. <i>Viruses</i> , 2019 , 11,	6.2	10
66	Some Aspects of CD8+ T-Cell Exhaustion Are Associated With Altered T-Cell Mitochondrial Features and ROS Content in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 82, 211-219	3.1	4
65	Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals. <i>Aids</i> , 2019 , 33, 1315-1325	3.25	36
64	Cancer and AIDS. 2019 ,		
63	Establishment of a Novel Humanized Mouse Model To Investigate Activation and Depletion of Patient-Derived HIV Latent Reservoirs. <i>Journal of Virology</i> , 2019 , 93,	6.6	16
62	Clinical pharmacology in HIV cure research - what impact have we seen?. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 17-29	3.8	3

61	Bispecific antibodies: Potential immunotherapies for HIV treatment. <i>Methods</i> , 2019 , 154, 118-124	4.6	12
60	Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors. <i>AIDS Research and Human Retroviruses</i> , 2019 , 35, 1-24	1.6	16
59	Broad Recognition of Circulating HIV-1 by HIV-1-Specific Cytotoxic T-Lymphocytes with Strong Ability to Suppress HIV-1 Replication. <i>Journal of Virology</i> , 2019 , 93,	6.6	11
58	Strategies for the cure of HIV infection. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019 , 37, 265-273.9		2
57	Evolution and Diversity of Immune Responses during Acute HIV Infection. <i>Immunity</i> , 2020 , 53, 908-924	32.3	5
56	PEBP1 suppresses HIV transcription and induces latency by inactivating MAPK/NF- κ B signaling. <i>EMBO Reports</i> , 2020 , 21, e49305	6.5	7
55	Role of Escape Mutant-Specific T Cells in Suppression of HIV-1 Replication and Coevolution with HIV-1. <i>Journal of Virology</i> , 2020 , 94,	6.6	4
54	Association of Viral Persistence and Atherosclerosis in Adults With Treated HIV Infection. <i>JAMA Network Open</i> , 2020 , 3, e2018099	10.4	5
53	Benefits of antiretroviral therapy initiation during acute HIV infection. <i>Acta Clinica Belgica</i> , 2020 , 1-9	1.8	1
52	Advances in Developing CAR T-Cell Therapy for HIV Cure. <i>Frontiers in Immunology</i> , 2020 , 11, 361	8.4	19
51	HIV-1 Tat: Role in Bystander Toxicity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 61	5.9	24
50	Effective Activation of Human Antigen-Presenting Cells and Cytotoxic CD8 T Cells by a Calcium Phosphate-Based Nanoparticle Vaccine Delivery System. <i>Vaccines</i> , 2020 , 8,	5.3	13
49	CD4CD38 central memory T cells contribute to HIV persistence in HIV-infected individuals on long-term ART. <i>Journal of Translational Medicine</i> , 2020 , 18, 95	8.5	5
48	Block-And-Lock Strategies to Cure HIV Infection. <i>Viruses</i> , 2020 , 12,	6.2	48
47	HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy. <i>Expert Review of Vaccines</i> , 2020 , 19, 71-84	5.2	7
46	HIV-1 cure strategies: why CRISPR?. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 781-793	5.4	4
45	Etiology and pathophysiology of heart failure in people with HIV. <i>Heart Failure Reviews</i> , 2021 , 26, 497-505		1
44	CD8 lymphocyte depletion enhances the latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques. <i>Journal of Virology</i> , 2021 ,	6.6	8

43	Evaluating a New Class of AKT/mTOR Activators for HIV Latency Reversing Activity. <i>Journal of Virology</i> , 2021 ,	6.6	3
42	Abnormal Tryptophan Metabolism in HIV and Infection. <i>Frontiers in Microbiology</i> , 2021 , 12, 666227	5.7	1
41	Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir. <i>PLoS Pathogens</i> , 2021 , 17, e1009686	7.6	0
40	Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity. <i>Vaccines</i> , 2021 , 9,	5.3	2
39	STING Ligand-Mediated Priming of Functional CD8 T Cells Specific for HIV-1-Protective Epitopes from Naive T Cells. <i>Journal of Virology</i> , 2021 , 95, e0069921	6.6	
38	FKBP3 Induces Human Immunodeficiency Virus Type 1 Latency by Recruiting Histone Deacetylase 1/2 to the Viral Long Terminal Repeat. <i>MBio</i> , 2021 , 12, e0079521	7.8	1
37	New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models. <i>Viruses</i> , 2021 , 13,	6.2	3
36	Evaluation of HIV-1 reservoir size and broadly neutralizing antibodies (bNAbs) susceptibility in acute ART treated individuals. <i>Aids</i> , 2021 ,	3.5	
35	Design, Synthesis and Docking Studies of Thioimidazolyl Diketoacid Derivatives Targeting HIV-1 Integrase. <i>Medicinal Chemistry</i> , 2021 ,	1.8	0
34	Dendritic cell targeted HIV-1 gag protein vaccine provides help to a recombinant Newcastle disease virus vectored vaccine including mobilization of protective CD8 T cells. <i>Immunity, Inflammation and Disease</i> , 2018 , 6, 163-175	2.4	4
33	Epigenetic crosstalk in chronic infection with HIV-1. <i>Seminars in Immunopathology</i> , 2020 , 42, 187-200	12	13
32	Epidemiology, pathophysiology, and prevention of heart failure in people with HIV. <i>Progress in Cardiovascular Diseases</i> , 2020 , 63, 134-141	8.5	8
31	Kinetics of Plasma HIV Rebound in the Era of Modern Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020 , 222, 1655-1659	7	8
30	Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. <i>Journal of Clinical Investigation</i> , 2017 , 127, 269-279	15.9	110
29	TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4387-4396	15.9	36
28	Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules. <i>PLoS ONE</i> , 2016 , 11, e0151572	3.7	12
27	Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. <i>PLoS Pathogens</i> , 2016 , 12, e1005983	7.6	26
26	Biomarker reveals HIV-1 hidden reservoir. <i>ELife</i> , 2014 , 3, e04742	8.9	5

25	Selective elimination of host cells harboring replication-competent human immunodeficiency virus reservoirs: a promising therapeutic strategy for HIV cure. <i>Chinese Medical Journal</i> , 2021 , 134, 2776-2787	2.9	3
24	The Tat Protein Enhances CTL Responses and Therapeutic Immunity of Gag-Specific Exosome-Targeted T Cell-Based Gag/Tat-Texo Vaccine in Transgenic HLA-A2 Mice. <i>World Journal of Vaccines</i> , 2017 , 07, 11-25	0.4	
23	Strategies for Progress. 2019 , 3-43		
22	Distinct mechanisms of long-term virologic control in two HIV-infected individuals after treatment interruption of anti-retroviral therapy. <i>Nature Medicine</i> , 2021 , 27, 1893-1898	50.5	2
21	HIV cure research: a formidable challenge. <i>Journal of Virus Eradication</i> , 2015 , 1, 1-3	2.8	13
20	Immune checkpoints and the HIV-1 reservoir: proceed with caution. <i>Journal of Virus Eradication</i> , 2016 , 2, 183-6	2.8	9
19	The latest science from the IAS Towards an HIV Cure Symposium: 16-17 July 2016, Durban, South Africa. <i>Journal of Virus Eradication</i> , 2016 , 2, 235-241	2.8	1
18	Establishment of latent HIV-1 reservoirs: what do we really know?. <i>Journal of Virus Eradication</i> , 2019 , 5, 3-9	2.8	32
17	In Situ Multiplexing to Identify, Quantify, and Phenotype the HIV-1/SIV Reservoir Within Lymphoid Tissue.. <i>Methods in Molecular Biology</i> , 2022 , 2407, 277-290	1.4	
16	Single-Cell Sequencing Facilitates Elucidation of HIV Immunopathogenesis: A Review of Current Literature.. <i>Frontiers in Immunology</i> , 2022 , 13, 828860	8.4	0
15	Image_1.png. 2019 ,		
14	Image_2.png. 2019 ,		
13	Table_1.docx. 2019 ,		
12	Table_2.docx. 2019 ,		
11	data_sheet_1.PDF. 2018 ,		
10	HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys.. <i>PLoS Pathogens</i> , 2022 , 18, e1010467	7.6	2
9	Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection. <i>Disease Markers</i> , 2022 , 2022, 1-10	3.2	0
8	Combination anti-HIV antibodies provide sustained virological suppression. <i>Nature</i> ,	50.4	3

7	T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial. <i>Journal of Immunology</i> , 2022 , 208, 2663-2674	5.3	1
6	HIV cure strategies: which ones are appropriate for Africa?. <i>Cellular and Molecular Life Sciences</i> , 2022 , 79,	10.3	0
5	The HIV Reservoir and Cure and Remission Strategies. 2021 , 199-217		
4	Forging a Functional Cure for HIV: Transcription Regulators and Inhibitors. 2022 , 14, 1980		1
3	Prevalence and factors associated with late diagnosis among older adults living with HIV in liuzhou, China: 2010-2020. 2023 , 95,		0
2	Autophagy inducer rapamycin treatment reduces IFN- γ -mediated Inflammation and improves anti-HIV-1 T cell response in vivo. 2022 , 7,		0
1	Secreted factors induced by PKC modulators do not indirectly cause HIV latency reversal. 2023 , 581, 8-14		0